1. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone. (24th October 2016) Authors: Lin, Jianqing; Patel, Sheel A.; Sama, Ashwin R.; Hoffman-Censits, Jean H.; Kennedy, Brooke; Kilpatrick, Deborah; Ye, Zhong; Yang, Hushan; Mu, Zhaomei; Leiby, Benjamin; Lewis, Nancy; Cristofanilli, Massimo; Kelly, William Kevin Journal: Oncologist Issue: Volume 21:Number 11(2016) Page Start: 1296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration‐Resistant Prostate Cancer Progressing on Abiraterone. (24th October 2016) Authors: Lin, Jianqing; Patel, Sheel A.; Sama, Ashwin R.; Hoffman‐Censits, Jean H.; Kennedy, Brooke; Kilpatrick, Deborah; Ye, Zhong; Yang, Hushan; Mu, Zhaomei; Leiby, Benjamin; Lewis, Nancy; Cristofanilli, Massimo; Kelly, William Kevin Journal: Oncologist Issue: Volume 21:Number 11(2016) Page Start: 1296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients. (2015) Authors: Lin, Jianqing; Deng, Aileen; Hoffman-Censits, Jean; Gibney, Geoffrey; Hyslop, Terry; Miller, Brooke; Kilpatrick, Deborah; Jabbour, Serge; Kevin Kelly, William Journal: Cancer treatment communications Issue: Volume 4(2016)Supplement 1 Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗